Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAapro, Mattien_UK
dc.contributor.authorCameron, David Aen_UK
dc.contributor.authorPettengell, Ruthen_UK
dc.contributor.authorBohlius, Juliaen_UK
dc.contributor.authorCrawford, Jeffreyen_UK
dc.contributor.authorEllis, Michaelen_UK
dc.contributor.authorKearney, Noraen_UK
dc.contributor.authorLyman, Gary Hen_UK
dc.contributor.authorTjan-Heijnen, Vivianne Cen_UK
dc.contributor.authorWalewski, Janen_UK
dc.contributor.authorWeber, D Cen_UK
dc.contributor.authorZielinski, Christophen_UK
dc.description.abstractChemotherapy-induced neutropenia is not only a major risk factor for infection-related morbidity and mortality, but is also a significant dose-limiting toxicity in cancer treatment. Patients developing severe (grade 3/4) or febrile neutropenia (FN) during chemotherapy frequently receive dose reductions and/or delays to their chemotherapy. This may impact on the success of treatment, particularly when treatment intent is either curative or to prolong survival. The incidence of severe or FN can be reduced by prophylactic treatment with granulocyte-colony stimulating factors (G-CSFs), such as filgrastim, lenograstim or pegfilgrastim. However, the use of G-CSF prophylactic treatment varies widely in clinical practice, both in the timing of therapy and in the patients to whom it is offered. While several academic groups have produced evidence-based clinical practice guidelines in an effort to standardise and optimise the management of FN, there remains a need for generally applicable, European-focused guidelines. To this end, we undertook a systematic literature review and formulated recommendations for the use of G-CSF in adult cancer patients at risk of chemotherapy-induced FN. We recommend that patient-related adverse risk factors such as elderly age (P65 years), be evaluated in the overall assessment of FN risk prior to administering each cycle of chemotherapy. In addition, when using a chemotherapy regimen associated with FN in >20% patients, prophylactic G-CSF is recommended. When using a chemotherapy regimen associated with FN in 10–20% patients, particular attention should be given to patient-related risk factors that may increase the overall risk of FN. In situations where dose-dense or dose-intense chemotherapy strategies have survival benefits, prophylactic G-CSF support is recommended. Similarly, if reductions in chemotherapy dose intensity or density are known to be associated with a poor prognosis, primary G-CSF prophylaxis may be used to maintain chemotherapy. Finally, studies have shown that filgrastim, lenograstim and pegfilgrastim have clinical efficacy and we recommend the use of any of these agents to prevent FN and FN-related complications, where indicated.en_UK
dc.relationAapro M, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC & Zielinski C (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer, 42 (15), pp. 2433-2453.
dc.rightsThe publisher does not allow this work to be made publicly available in this Repository. Please use the Request a Copy feature at the foot of the Repository record to request a copy directly from the author; you can only request a copy if you wish to use this work for your own research or private study.en_UK
dc.subjectAntineoplastic agentsen_UK
dc.subjectGranulocyte colony-stimulatingen_UK
dc.subjectLenograstim factoren_UK
dc.subjectCancer Researchen_UK
dc.subjectChemotherapy, Adjuvant methodsen_UK
dc.subjectCancer Chemotherapyen_UK
dc.subjectAntineoplastic agentsen_UK
dc.titleEORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursen_UK
dc.typeJournal Articleen_UK
dc.rights.embargoreason[Aapro - EORTC guidelines for the use of Gr....pdf] The publisher does not allow this work to be made publicly available in this Repository therefore there is an embargo on the full text of the work.en_UK
dc.citation.jtitleEuropean Journal of Canceren_UK
dc.type.statusVoR - Version of Recorden_UK
dc.contributor.affiliationEuropean School of Oncologyen_UK
dc.contributor.affiliationUniversity of Stirlingen_UK
dc.contributor.affiliationUniversity of Londonen_UK
dc.contributor.affiliationUniversity of Cologneen_UK
dc.contributor.affiliationDuke Universityen_UK
dc.contributor.affiliationUnited Arab Emirates Universityen_UK
dc.contributor.affiliationHealth Sciences Research - Stirling - LEGACYen_UK
dc.contributor.affiliationUniversity of Rochesteren_UK
dc.contributor.affiliationRadboud University Nijmegenen_UK
dc.contributor.affiliationThe Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncologyen_UK
dc.contributor.affiliationGeneva University Hospitalen_UK
dc.contributor.affiliationVienna General Hospitalen_UK
rioxxterms.typeJournal Article/Reviewen_UK
local.rioxx.authorAapro, Matti|en_UK
local.rioxx.authorCameron, David A|en_UK
local.rioxx.authorPettengell, Ruth|en_UK
local.rioxx.authorBohlius, Julia|en_UK
local.rioxx.authorCrawford, Jeffrey|en_UK
local.rioxx.authorEllis, Michael|en_UK
local.rioxx.authorKearney, Nora|en_UK
local.rioxx.authorLyman, Gary H|en_UK
local.rioxx.authorTjan-Heijnen, Vivianne C|en_UK
local.rioxx.authorWalewski, Jan|en_UK
local.rioxx.authorWeber, D C|en_UK
local.rioxx.authorZielinski, Christoph|en_UK
local.rioxx.projectInternal Project|University of Stirling|
local.rioxx.filenameAapro - EORTC guidelines for the use of Gr....pdfen_UK
Appears in Collections:Faculty of Health Sciences and Sport Journal Articles

Files in This Item:
File Description SizeFormat 
Aapro - EORTC guidelines for the use of Gr....pdfFulltext - Published Version308.8 kBAdobe PDFUnder Embargo until 2999-12-06    Request a copy

This item is protected by original copyright

Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

The metadata of the records in the Repository are available under the CC0 public domain dedication: No Rights Reserved

If you believe that any material held in STORRE infringes copyright, please contact providing details and we will remove the Work from public display in STORRE and investigate your claim.